Future Market Insights has announced the addition of the “Insulin Biosimilars Market: Global Industry Analysis and Opportunity Assessment 2016 - 2026" report to their offering.

1. sales@futuremarketinsights.com
Global
Insulin Biosimilars
Market
Share, Global Trends,
Analysis, Research, Report,
Opportunities,
Segmentation and Forecast,
2016-2026
www.futuremarketinsights.comFuture Market Insights

2. Customized
Research
Syndicated
Research
Investment
Research
Social Media
Research
Future Market Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting
services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes,
technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends.
We provide research services at a global as well as regional level; key regions include GCC, ASEAN, and BRIC.
Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and
Retail.
We have a global presence with delivery centers across India specializing in providing global research reports and country
research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India.
We combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solution for
our client.
Research Capabilities
Subscription Information
 Customized Research
 Syndicated Research
 Investment Research
 Social Media Research
Sector Coverage
 Automotive and Transportation
 Electronics, Semiconductor, and ICT
 Retail and Consumer Products
 Industrial Automation and Equipment
 Chemicals & Materials
 Food and Beverages
 Services and Utilities
 Energy, Mining, Oil, and Gas
For detailed subscription information please contact
Hari. T (Sr. Manager - Global Business Development)
T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268
Email: hari.t@futuremarketinsights.com

3. A new race has been initiated between biosimilar and branded drug manufacturers to
gain maximum revenue share from insulin market. The upcoming three years are very
crucial for insulin manufacturers, as most of the branded insulin are going to be off
patent which would results into the loss of around US$53 Bn revenue for branded
manufacturers in 2016. Generic manufacturers are expected to take smaller chunk of this
amount owing to their local presence which would restrain them take share from other
markets. In such dynamic situation, the original drug manufacturers are seeking for plan
B to sustain their hold in the market. As a result, these companies are now integrated
with biosimilar manufacturers through agreement, alliance. Moreover, legal troubles
pertaining patent infringement is hampering the development insulin Biosimilars. In
order to overcome such infringement issues, the companies are now collaborating with
each other to develop biosimilars versions of insulin. Recent example of global
collaboration agreement between Mylan N.V. and Momenta Pharmaceuticals, Inc. has
provided a competitive advantage to Mylan by increasing the number of insulin
biosimlars under development. This collaboration will capitalized Mylan’s existing
portfolio of biologics and insulin analog development.
Insulin Biosimilars Market: Drivers and Restraints
Increasing prevalence of Type I diabetes, higher cost of existing insulin drugs are
expected to drive growth of insulin biosimilars market. Government authorities are also
focusing on the approval of insulin biosimilars owing to substantial financial burden in
terms of reimbursements. Recently, the U.S. FDA has approved new insulin glargine
Report DescriptionReport Description

4. Basaglar, for type 1 and type 2 diabetes which is Biosimilar version of Sanofi’s basal
insulin Lantus (insulin glargine). Additionally, Lilly and Boehringer Ingelheim's biosimilar
insulin glargine has got approval through European Medicines Agency's (EMA's)
Biosimilar pathway. Such ongoing approvals by the respective authorities are expected to
drive the growth of insulin Biosimilar market. However, Insulin patent protection rights
and strong retaliation from the branded manufactures has restricted the growth of
insulin biosimilar development.
Request Free Report Sample @
http://www.futuremarketinsights.com/reports/sample/rep-gb-1883
Insulin Biosimilars Market: Segmentation
The global market for insulin Biosimilar is segmented on the basis of disease indication
and geography.
On the basis of disease indication, the global insulin Biosimilar market is segmented as,
• Type I Diabetes
• Type II Diabetes
Insulin Biosimilars Market: Overview
Development of clinically proven insulin Biosimilar will pave the road for new entrants.
The upcoming patent expiration of blockbuster insulin drugs will open a new avenue and
Report DescriptionReport Description

5. unprecedented opportunities for biosimilar development and manufacturing companies.
The cost of insulin biosimilar is currently high owing to stringent adherence requirements
in terms of complex regulations and manufacturing and operations. Prices of biosimilar
drugs are expected decreased by an average of 20% as compared to branded drugs.
Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1883
Insulin Biosimilars Market: Region-wise Outlook
Geographically, the global insulin biosimilar market is segmented into regions namely,
North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific Excluding
Japan, Japan, Middle East and Africa. Among all the regions, North America will continue
to lead the global market for insulin biosimilars market due to high demand for insulin.
Europe insulin market is expected to account for second largest share in global market
primarily due to early approval for biosimilar which is expected to fuel the market
growth. Asian companies are competing on the basis of price and has patient pool
suffering diabetes. Hence, the Asia Pacific insulin biosimilar market is expected to witness
fastest growth in overall market over the forecast period.
Insulin Biosimilars Market: Key Players
Key players operating in the global insulin biosimilar market are Eli Lilly & Co.,
Boehringer Ingelheim, Merck & Co., Pfizer Inc., Biocon, Mylan N.V. and others
Browse Full Report@ http://www.futuremarketinsights.com/reports/insulin-biosimilars-
market
Report DescriptionReport Description

6. Thank You!
To know more about us, please visit our website:
www.futuremarketinsights.com
For sales queries or new topics email us on:
sales@futuremarketinsights.com
Future Market Insights: 616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
T: +1-347-918-3531 | D: +1-845-579-5705